Rhumbline Advisers Adicet Bio, Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 20,819 shares of ACET stock, worth $29,562. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,819
Previous 60,496
65.59%
Holding current value
$29,562
Previous $142,000
82.39%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ACET
# of Institutions
95Shares Held
66.3MCall Options Held
4.3KPut Options Held
36.3K-
Orbimed Advisors LLC San Diego, CA11.4MShares$16.3 Million0.33% of portfolio
-
Tang Capital Management LLC San Diego, CA8.22MShares$11.7 Million1.21% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.54MShares$10.7 Million0.14% of portfolio
-
Goldman Sachs Group Inc New York, NY4.28MShares$6.08 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.62MShares$5.14 Million0.0% of portfolio
About Adicet Bio, Inc.
- Ticker ACET
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,030,800
- Market Cap $56.8M
- Description
- Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...